Our tests use patented technology to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
Our accurate and reliable tests meet the demands of patients, clinicians and payers for non-invasive, pain-free, healthcare technologies which not only improve patient care but reduce healthcare costs.
ADXBLADDER is the first of Arquer’s MCM5 tests to be released as a CE marked bladder cancer test and we are also currently testing the technology in prostate and endometrial cancers.